§ Review mechanism of action of PCSK9 inhibitors § Outcome Trial Results with PCSK9 Inhibitors § Results of Recent Improve-It Trial § New therapies on the horizon. Comparison of two P2Y12 inhibitors in ACS patients with diabetes Literature - Nov. 9, 2020 - Ndrepepa G, et al. PCSK9 inhibitors – mechanisms of action injections cause a sustained reduction of about 50–70% from baseline, as monotherapy or when added to a statin.11-13 Lipoprotein(a) PCSK9 inhibition also decreases the plasma concentrations of lipoprotein(a) (Lp(a)) by around 20–30%.11,13 This particle is similar in size and cholesterol content to LDL. Describe the mechanism of action of and indications for PCSK9 inhi bitors, SGLT2 inhibitors, and high dose omega-3-polyunsaturated fatty acids • No competing interests /financial relationships to disclose • I will discuss what is currently off-label use of icosapent ethyl (Vascepa®) • Branded Rx/OTC products shown: not an endorsement LDL particles are taken up via LDL receptors, primarily on hepatocytes, and degraded. A mechanism of action animation on the role of PCSK9 in the regulation of LDL cholesterol. ... A mechanism of action animation on the role of PCSK9 in the regulation of LDL cholesterol. ... HMG-CoA Reductase Inhibitor: Mechanism of Action Source: McKenney JM. The mechanisms of action of PCSK9 inhibitors on lipoprotein metabolism and atherosclerosis, as well as their impact on cardiovascular outcomes and cost-effectiveness remain to be established. 2. Although their exact mechanism of action remains under study, recent evidence suggests that PCSK9 inhibitors may reduce Lp(a) concentration by both enhancing clearance 24 and reducing its production. Pathogenesis of Atherosclerosis § Atherosclerosis is a DIFFUSE DISEASE driven by inflammation, atherogenic - Mechanism of action of statins and anti-PCSK9 monoclonal antibodies VLDL is secreted by the liver and converted to LDL, which delivers cholesterol to peripheral tissues and is atherogenic. PCSK9 inhibitors (Monoclonal antibodies) Alirocumab Evolocumab Bococizumab .